Suchergebnisse - "Kallend, David"

PubPharm (114)

1

Effect of lipid-lowering therapies on C-reactive protein levels : a comprehensive meta-analysis of randomized controlled trials

enthalten in: Cardiovascular research | 2024

von Xie, S. | Galimberti, F. | Olmastroni, E. | +26

2

Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (PCSK9) protein reduction

enthalten in: Europäisches Patentamt | 2023

von WIJNGAARD PETER | KALLEND DAVID

3

Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia : the LIBerate-HeFH trial

enthalten in: European heart journal | 2023

von Raal, F. | Fourie, N. | Scott, R. | +37

4

The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions

enthalten in: Pharmacology research & perspectives | 2023

von Lehoux, D. | Kallend, D. | Wijngaard, P. | +2

5

Inclisiran and cardiovascular events : a patient-level analysis of phase III trials

enthalten in: European heart journal | 2023

von Ray, K. | Raal, F. | Kallend, D. | +10

CommentIn: Eur Heart J. 2023 Jan 7;44(2):139-141. - PMID 36331316

6

The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions

enthalten in: Pharmacology Research & Perspectives | 2023

von Lehoux, D. | Kallend, D. | Wijngaard, P. | +2

7

Effect of inclisiran on lipids in primary prevention : the ORION-11 trial

enthalten in: European heart journal | 2022

von Ray, K. | Kallend, D. | Leiter, L. | +8

CommentIn: Eur Heart J. 2022 Dec 21;43(48):5058-5060. - PMID 36331327

8

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers : A phase I, randomized study

enthalten in: Clinical and translational science | 2022

von Kallend, D. | Mason, J. | Smith, P. | +4

9

Corrigendum to "Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys" [Toxicology and Applied Pharmacology 443 (2022) 115978

enthalten in: Toxicology and applied pharmacology | 2022

von Lehoux, D. | Far, A. | Kallend, D. | +2

ErratumFor: Toxicol Appl Pharmacol. 2022 May 15;443:115978. - PMID 35288146

10

Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys

enthalten in: Toxicology and applied pharmacology | 2022

von Lehoux, D. | Far, A. | Kallend, D. | +2

ErratumIn: Toxicol Appl Pharmacol. 2022 Jun 30;:116144. - PMID 35780943

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]